Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

Circulation

Volumn 97, Issue 15, 1998, Pages 1453-1460

  Pedersen, Terje R ^a   Olsson, Anders G ^e   Færgeman, Ole ^e   Kjekshus, John ^e   Wedel, Hans ^b   Berg, Kåre ^e   Wilhelmsen, Lars ^b   Haghfelt, Torben ^e   Thorgeirsson, Gudmundur ^c   Pyörälä, Kalevi ^e   Miettinen, Tatu ^e   Christophersen, Bjørn ^e   Tobert, Jonathan A ^d   Musliner, Thomas A ^d   Cook, Thomas J ^d  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Aker Hospital ^*

Author keywords

Cholesterol; Coronary disease; Lipoproteins; Simvastatin

Indexed keywords

SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK MANAGEMENT; SECONDARY PREVENTION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032554686     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.15.1453     Document Type: Article

References (28)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
2. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG. Pyörälä K, Thorgeirsson G, Tobert JA, Wedel H, Wilhelmsen L. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1996;156:2085-2092.
3. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.
4. Kjekshus J, Pedersen TR, for the Scandinavian Simvastatin Survival Study Group. Reducing the risk of coronary events: evidence from 4S. Am J Cardiol. 1995;76:64C-68C.
5. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
6. Wolfe RA, Strawderman RL. Logical and statistical fallacies in the use of Cox regression models. Am J Kidney Dis. 1996;27:124-129.
7. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984; 251:365-374.
8. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641-651.
9. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology. European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300-1331.
10. Expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
11. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256: 2823-2828.
12. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Nedeljkovic S, Nissinen A, Toshima H. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: twenty-five-year follow-up of the Seven Countries Study. JAMA. 1995;274: 131-136.
13. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease: the Framingham Study. Ann Epidemiol. 1992;2:23-28.
14. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Smith SC Jr, Washington R. When to start cholesterol-lowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation. 1997;95:1683-1685.
15. The National Institutes of Health Consensus Development Conference on Triglyceride, HDL, and Coronary Heart Disease. Triglyceride, High Density Lipoprotein, and Coronary Heart Disease. NIH Consensus Statement (Feb. 26-28, 1992). 1992:10.
16. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
17. Assmann G, Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study. Eur J Epidemiol. 1992;1:99-103.
18. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69-75.
19. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb. 1992;12:1336-1345.
20. Szatrowski TP, Peterson AV Jr, Shimizu Y, Prentice RL, Mason MW, Fukunaga Y, Kato H. Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort. J Chronic Dis. 1984;37:569-584.
21. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991;303:276-282.
22. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol, and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
23. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
24. Burchfiel CM, Laws A, Benfante R, Goldberg RJ, Hwang L, Chiu D, Rodriguez B, Curb JD, Sharp DS. Combined effects of HDL cholesterol, triglyceride, and total cholesterol concentrations on 18-year risk of atherosclerotic disease. Circulation. 1995;92:1430-1436.
25. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-372.
26. Gordon DJ. Cholesterol lowering and total mortality. In: Rifkind BM, ed. Lowering Cholesterol in High Risk Individuals and Populations. New York, NY: Marcel Dekker; 1995:33-47.
27. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 1998;97:946-952.
28. Davidson MH, Stein EA, Dujovne CA, Hunninghake DB, Weiss SR, Knopp RH. Illingworth DR, Mitchel YB, Melino MR, Zupkis RV, Dobrinska MR, Amin RD, Toben JA. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol. 1997;79:38-42.